On this page
Study tools
Write your answer
Saved on this device. No marking — you are the marker.
Stem
A 31-year-old woman, gravida 4 para 0, presents at 9 weeks of gestation with vaginal bleeding for 2 days. She has had three consecutive first-trimester losses in the past four years. She is otherwise well, takes no regular medication, and is Rh-negative. On speculum examination the cervical os is closed; transvaginal ultrasound shows a live intrauterine fetus with a crown-rump length of 22 mm and a positive fetal heartbeat. [1]
[1]Questions
a) Define recurrent pregnancy loss and state the single most common identifiable cause. (2 marks) [1]
[1]RCOG Green-top Guideline No. 17 defines recurrent miscarriage as the loss of three or more consecutive pregnancies (about 1 percent of couples trying to conceive). International guidelines do not agree on a single numeric definition. The most important treatable cause is antiphospholipid syndrome (APS), diagnosed by persistent lupus anticoagulant, anticardiolipin, or anti-beta-2-glycoprotein-I antibodies.[1][2]
b) List the structured investigations you would perform for this woman's recurrent losses. (3 marks) [1]
[1]- Parental peripheral blood karyotype — balanced reciprocal translocation (3 to 5 percent of couples with RPL).
- Antiphospholipid antibodies — lupus anticoagulant, anticardiolipin (IgG/IgM), anti-beta-2-glycoprotein-I (repeat at 12 weeks to confirm persistence).
- Pelvic imaging — 3D ultrasound or saline infusion sonohysterography / hysteroscopy to detect uterine anomalies (septum); hysterosalpingography if needed.
- Endocrine — TSH, HbA1c (thyroid disease, diabetes).
- Inherited thrombophilia screen — factor V Leiden, prothrombin gene mutation, protein C/S, antithrombin (if a late loss or strong family history).
- Karyotype of products from any future loss (if available).[1]
c) Her APS screen returns persistently positive. What specific treatment improves her chance of a live birth, and when is it started? (3 marks) [1]
[1]- Aspirin plus heparin (RCOG Green-top 17: aspirin plus unfractionated heparin versus aspirin alone reduces the miscarriage rate by 54 percent, RR 0.46).
- International RPL guidelines (ESHRE, ASRM, RCOG) agree on this combination for obstetric APS. Warfarin is teratogenic and is not used for this indication.
- Do not extrapolate this regimen to inherited thrombophilia: ALIFE2 found no live-birth benefit from LMWH (72 percent vs 71 percent).[2][5]
d) Despite treatment she later has a heavy bleed at 10 weeks with an open cervical os and tissue at the os. She is Rh-negative. Outline your immediate management. (2 marks) [1]
[1]- Assess ABCs and haemodynamic status; secure IV access, send FBC and group and save.
- Diagnose incomplete miscarriage (open os, partial passage of products, ongoing heavy bleeding).
- Proceed to surgical evacuation (suction) for heavy bleeding. She is 10 weeks and Rh-negative: NICE NG126 (2026) does not offer anti-D up to and including 11+6 weeks — document the decision; anti-D at least 250 IU is offered at 12+0 to 12+6 weeks if medical or surgical management is used.
- Offer empathic support and follow-up counselling. Antibiotics if any features of sepsis.[1]
References5ShowHide
- [1]Deng T, Liao X, Zhu S. Recent Advances in Treatment of Recurrent Spontaneous Abortion. Obstetrical and Gynecological Survey, 2022.PMID 35672876
- [2]Jeve YB, Davies W. Evidence-based management of recurrent miscarriages. Journal of Human Reproductive Sciences, 2014.PMID 25395740
- [3]Chu JJ, Devall AJ, Beeson LE, et al. Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (MifeMiso): a randomised, double-blind, placebo-controlled trial. The Lancet, 2020.PMID 32853559
- [4]Coomarasamy A, Devall AJ, Cheed V, et al. A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy. New England Journal of Medicine, 2019.PMID 31067371
- [5]Quenby S, Booth K, Hiller L, et al. Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial. The Lancet, 2023.PMID 37271152